Fundus Image Grading
Diagnostic TestThe image is graded by a fully automated AI device
NCT Number: NCT07222293
A study will be conducted to demonstrate that DRISTi will correctly diagnose Diabetic Retinopathy (e.g., mtmDR, PDR, DME) in eyes of patients with diabetes. Participants who have been diagnosed with diabetes mellitus and meet the other inclusion/exclusion criteria will be invited to participate and will consent to have ophthalmic images taken. These images will be analyzed by DRISTi AI software and evaluated by an ophthalmic reading center. The results will be compared, and a statistical analysis will be completed to ensure statistical significance in the outcomes thus proving DRISTi is an effective DR diagnosis tool.
Interested in participating?
Request Info21 year and older
All sexes
Observational
New Century Ophthalmology - Oxford, Oxford, North Carolina, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The image is graded by a fully automated AI device
Time frame: From time of arrival to completion of diagnostic tests, up to 8 hours
AI generated image grades are directly compared to a Human generated image grade
Contact information is provided by the study sponsor or research team.
Adriana Valencia, Site Coordinator Raleigh
CONTACT
Jeanne Champion, Primary Site Coordinator Oxford
CONTACT
Artelus AI
Industry
Assessment of 'DRISTi' as an Automated Diabetic Retinopathy Screening Tool in Diabetic Populations
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07378956
Cardiovascular Diseases, Diabete Mellitus
Incheon, Gyeonggi-do, South Korea
View Trial DetailsNCT07351786
Cardiovascular Diseases, Diabetes (DM)
Alexandria, Egypt
View Trial DetailsNCT06968611
Cardiovascular Diseases, Diabetes Complications
Dinajpur, Bangladesh
View Trial DetailsNCT06968637
Cardiovascular Diseases, Diabetes Complications
Dinajpur Sadar, Dinajpur, Bangladesh
View Trial Details